Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: ed edelson + november 22  Related to the article below (Last Update: 7/8/2008)

Ankle-Arm Blood Pressure Test Predicts Heart Disease Risk
U.S. News & World Report, DC -
By Ed Edelson TUESDAY, July 8 (HealthDay News) -- A seldom-used test that measures blood pressure in the ankle and the arm can help improve assessment of ...
Omega-3, Some Omega-6 Fatty Acids Boost Cardiovascular Health
Washington Post, United States - Jul 7, 2008
By Ed Edelson MONDAY, July 7 (HealthDay News) -- High intake of the omega-3 fatty acids in oily fish and vegetable cooking oils appear to help prevent heart ...
Autism Research Institute Launches Mobile Website
Earthtimes (press release), UK -
According to Steve Edelson , director of the San Diego -based research and education group, this is the first .mobi Web site created and maintained by a ...

The News - International
These simple treatments help fight dryness, bumps and acne
The News - International, Pakistan -
... slurred speech or a droopy face, weakness in one side, partial vision loss and severe headache, according to the American Stroke Association. By Ed Edelson.
H3 Enterprises Inks Agreement With Online Video Gaming Pay-to-Play ...
Market Wire (press release) -
This agreement officially commences the initiation of H3's multi-faceted online video gaming revenue business model," said Jordan Edelson, H3 Enterprises' ...PINK:HTRE
Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates
Washington Post, United States - Jul 2, 2008
By Ed Edelson WEDNESDAY, July 2 (HealthDay News) -- Injecting the artery-constricting hormone vasopressin in addition to adrenaline did not improve survival ...
Opening Clogged Arteries Helps Women After Heart Attack
U.S. News & World Report, DC - Jul 1, 2008
By Ed Edelson TUESDAY, July 1 (HealthDay News) -- Contradicting some earlier reports, a new study finds that women who have heart attacks benefit as much as ...
Research Links Low HDL Levels With Memory Loss
U.S. News & World Report, DC - Jun 30, 2008
By Ed Edelson MONDAY, June 30 (HealthDay News) -- A new study suggests an association between low levels of "good" HDL cholesterol and loss of memory. ...
New Molecular Trigger Described for Hypertension, Diabetes
Washington Post, United States - Jun 30, 2008
By Ed Edelson MONDAY, June 30 (HealthDay News) -- A newly discovered molecular malfunction may explain the development of high blood pressure, diabetes and ...
'Silent Strokes' Strike One in 10 Healthy People
U.S. News & World Report, DC - Jun 26, 2008
By Ed Edelson THURSDAY, June 26 (HealthDay News) -- If you're an older American with no major health problems, chances are about one in 10 that you've had a ...
Source: Google News

Expression of the epithelial Na+ channel in the developing rat lung -
… C Canessa, J Ueda, B Rafii, BC Rossier, J Edelson - American Journal of Physiology- Cell Physiology, 1993 - Am Physiological Soc
... B. Rafii, BC Rossier and J. Edelson Department of ... alveolar epithelial cells J Appl
Physiol, November 1, 2002 ... X. Li, SM Zabski, KJ Kim, and ED Crandall Alveolar ...

TRA N SF USION MEDICI NE IL LUS TRAT ED
BT Edelson, JK Donnelly, TS Cox-Potter, KS Shah, … - TRANSFUSION, 2006 - ingentaconnect.com
... revision received November 16, 2005, and accepted November 22, 2005. ... TRA N SF USION
MEDICI NE IL LUS TRAT ED ... Brian T. Edelson, Jamie K. Donnelly, Tinna S. Cox ...

[CITATION] … Ten North Carolina Fiction Writers. A Master's paper for the MS in LS degree. November 2000. 44 pages …
AUG Edelson - 2000 - University of North Carolina

[PDF] Learning and Organizational Change 212 Learning and Understanding
R Lerner - sesp.northwestern.edu
... Byrnes, Chapter 5 (Edelson & Joseph, 2005) October 27 Concepts and Conceptual Change;
Science Education ... November 22: Second Midterm (45 minutes) Discussion of ...

Chemical shift nonequivalence of prochiral groups in the proton nuclear magnetic resonance spectra …
NF Bray, RL Baumgarten, E Edelson - Journal of Chemical and Engineering Data, 1977 - pubs.acs.org
... pharmco/., 22, ... Norman F. Bray,' Reuben L. Baumgarten,' and Edward Edelson Department
of Chemistry, Herbert H. Lehman College of the City University of New York ...
-

Handbook of Distance Education -
AT Glossary - questia.com
... Charlottesville, VA: Association for the Advancement of Computing in Education.
Goodyear, P. (2000 November 17 th ). ... Gordin, DN, Edelson, DC, & Gomez, LM (1996 ...
-

A New Preparation of Symmetrical y-Diketones"
NJ Turro, SS Edelson, T Darling, D Graham - J. Org. Chem - doi.wiley.com
... Ed. ... A. E. Hil1,G. Greenwood, HMR Hoffmann,ibid.95,1338(1973).-(6b): N . J. Turro,
SS Edelson, J. R ... Received: November 25, 1977 [Z 890 JE] German version: Angew. ...

[PDF] Nuclear Energy -
N Energy - Journal of the British Nuclear Energy Society, 2000 - local.ans.org
... 9 16 1961 November 22. The US Navy commis- sions the world?s largest ship,
the USS Enterprise. It is a nuclear-powered aircraft ...

Structure of human factor VIII -
GA Vehar, B Keyt, D Eaton, H Rodriguez, DP O'Brien … - Nature, 1984 - nature.com
Nature 312, 337 - 342 (22 November 1984); doi:10.1038/312337a0. ... 2 (ed. Putnam,. ... 33.
Goldstein, IM, Kaplan, HB, Edelson, HS & Weissman, G. J. biol. Chem. ...

Normal levels of 5'-nucleotidase activity in lymphocytes from patients with X-linked … -
PJ Edelson, J Schwaber - Science, 1979 - sciencemag.org
... 26, 199 (1974); G. Jonsson, T. Malmfors, C. Sachs, Ed., 6-Hy- droxydopamine as a
Denervation Tool ... Granulo- cytes cytes cytes 1 25 36 27 2 28 44 26 3 22 21 56 4 ...
-

Source: Google Scholar
 
 

New Blood Thinner Offers Safer Heart Attack Care

November 22, 2006 03:58:07 PM PST
By Ed Edelson
HealthDay Reporter

WEDNESDAY, Nov. 22 (HealthDay News) -- A newer anti-clotting drug called bivalirudin (Angiomax) beats standard combination drug therapy for patients with acute coronary syndromes such as heart attacks, a new study finds.

"We use it at Columbia in the vast majority of cases," said lead researcher Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education at Columbia University. "We find that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

His team published the results of the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial in the Nov. 23 issue of the New England Journal of Medicine.

The study was funded by The Medicines Company and Nycomed, which market Angiomax.

The journal report described a trial involving nearly 14,000 patients with heart attack or other acute coronary syndromes. Participants were assigned to one of three drug regimens: a package treatment including heparin; a similar package including bivalirudin; or bivalirudin alone.

Article continues below and (thank you)

 

On the surface, the numbers coming out of the trial did not seem to favor bivalirudin. The overall incidence of major problems such as a second heart attack, death or the need for a second procedure to reopen a blocked artery were virtually identical between the two groups: 7.7 percent for the combo therapy including heparin vs. 7.3 percent for the bivalirudin package.

The overall incidence of such problems in the patients who got bivalirudin alone was also the same -- 7.3 percent.

However, only 3 percent of those getting bivalirudin alone had major bleeding episodes, compared to 5.7 percent of those getting the heparin package. For patients, that makes all the difference, Stone said.

Bivalrudin also reduced the incidence of artery blockage or major bleeding by about 14 percent compared to a drug package including heparin, the researchers found.

"It makes care of patients in the cath lab much simpler and safer," Stone said. "Cath lab" is medical shorthand for the catheterization facility where doctors perform angioplasty -- threading a tube into an artery so it can be reopened.

"The big difference was the reduction of major bleeding, almost 50 percent," Stone added. "Major bleeding has been associated with higher mortality, so it is important for the outcome."

Like most of the investigators in the ACUITY trial, Stone disclosed prior financial ties to a variety of drug makers, not only The Medicines Company and Nycomed but also companies that market competing brands of blood thinners.

"This report states that bivalirudin can be used for patents with acute coronary syndrome with a lower risk of bleeding than conventional treatment," added Dr. John A. Bittl, an interventional cardiologist at the Munroe Regional Medical Center in Ocala, Fla., who wrote an accompanying editorial.

In principle, bivalirudin could be reserved for patients at increased risk of bleeding episodes, such as those with anemia, Bittl said. "It has recently become apparent that anemia, when detected in the hospital, is a very important prognostic factor," he said. "It is not clear whether it is anemia itself or whether anemia is a marker of general health."

In practice, "We use bivalirudin in more than 90 percent of cases," Bittl said.

More information

There's more on acute coronary syndromes at the American Heart Association.

 

Fetal Oxygen Test Fails to Deliver

November 22, 2006 03:58:07 PM PST
By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Nov. 22 (HealthDay News) -- A new test that measures how much oxygen is circulating in fetal blood just before birth has no effect on whether delivery is done by Caesarean section or not, researchers report.

In addition, fetal blood oxygen doesn't appear to reflect the health of the newborn -- suggesting there's no real reason to use the test.

"We found absolutely no difference in Caesarean sections," said Dr. Steven Bloom, lead author of a study appearing in the Nov. 23 issue of the New England Journal of Medicine. "Given the available evidence -- and I believe we are the most definitive study -- there is no apparent benefit of this technology, which is not to say there won't be possibilities in the future."

Experts say the findings won't have much impact on obstetric practice.

"This is not a technology that is widespread in the U.S.," said Dr. Michael Divon, chairman of obstetrics and gynecology at Lenox Hill Hospital in New York City. "It also becomes somewhat irrelevant because so many C-sections are elective. It's very difficult to come up with a technology which decreases the C-section rate when so many are being done just because the patient wants it."

The C-section delivery rate stands at a record high in the United States as of last year, accounting for 30.2 percent of all births. That represents a 46 percent rate increase since 1996, according to the U.S. Centers for Disease Control and Prevention's latest statistics. C-sections carry several risks, including infection and a longer recovery time.

"Whatever we're doing obviously is not working because the C-section rate has reached a peak," said Dr. Abdulla Al-Khan, director of fetal diagnosis and therapeutics at Hackensack University Medical Center in Hackensack, N.J.

The device used to measure fetal oxygen in this study, called the OxiFirst Fetal Oxygen Saturation Monitoring System, was conditionally approved by the U.S. Food and Drug Administration in 2000 for use as an adjunct to electronic fetal monitoring. Electronic fetal monitoring remains the most widely used tool to evaluate the health of a baby during delivery. Much of the concern has to do with preventing cerebral palsy, which had been thought to be due to a lack of oxygen during labor.

Fetal pulse oximetry had been developed over a decade and generated a great deal of "buzz" in obstetrics circles. "People though this technology could potentially meaningfully change the way we manage women during labor and really help us assess the well-being of a baby during labor," Bloom explained.

FDA approval was based on a study of more than 1,000 women whose pregnancies were complicated by fetal heart rate problems. But although fetal pulse oximetry reduced the rate of C-sections due to "non-reassuring fetal heart rate patterns," it also greatly increased the number due to other complications.

"The results were a little perplexing," said Bloom, who is chairman of the department of obstetrics and gynecology at the University of Texas Southwestern Medical Center at Dallas.

Shortly after the release of those findings, the American College of Obstetricians and Gynecologists issued a strong statement recommending that obstetricians in the United States not adopt the device as a routine practice until further studies were conducted.

Enter the current study, which was conducted by the U.S. National Institute of Child Health and Human Development's Maternal/Fetal Medicine Units Network. "We tried to validate the findings," Bloom said.

This study involved 5,341 first-time mothers who were randomly assigned to receive either "open" or "masked" fetal pulse oximetry. In the former group, the doctor could see fetal oxygen saturation values while, in the latter, the values were recorded, but the physician could not see them.

For the study, special oximetry sensors were positioned near the fetus's face so as to be able to measure blood oxygen levels.

As it turned out, there was essentially no difference in overall rates of Caesarean delivery between the open and masked groups (26.3 percent in the open group and 27.5 percent in the masked group).

Although the study was originally designed to involve 10,000 women, it was stopped early because the results were so conclusive.

"We don't know why fetal pulse oximetry didn't work. We have given it a good chance. We tried it thousands of times," Bloom said.

Others faulted the study for excluding women with problems. "They essentially went for a completely normal group of patients, and we know that in that set of babies it's very difficult to cause bad things no matter what your testing is like," said Dr. Edward Davis, director of maternal fetal medicine at Hackensack University Medical Center.

There is still, however, a need for more successful technology, Bloom maintained.

"Electronic fetal monitoring has limitations, and there's just no getting around that," he said. "There is a need in obstetrics to develop additional tools to help us evaluate the well-being of the baby."

"Electronic fetal monitoring has a 50 percent false-positive rate so half the time we do a C section for [irregularities] it turns out the baby was doing fine," said Dr. Jesus Alvarez, senior fellow of maternal fetal medicine at New Jersey Medical School in Newark. "We're looking for other tools as this one clearly doesn't work."

It may also be that problems need to be picked up earlier on. "The incidence of cerebral palsy has not decreased," Al-Khan said. "That tells us this is a process that happens early in pregnancy. We're picking things up when the damage is already done."

More information

To learn more about a healthy pregnancy, visit the U.S. Centers for Disease Control and Prevention.

 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 

 © 2002-2006

Keywords::

Contact Iconocast

Home Page